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Abstract
Introduction: Oral mucositis (OM) is an unavoidable condition of the oral cavity that accompanies 
chemotherapy for various malignant cases. Chemotherapy-induced oral Mucositis (COM) is a 
frequent complication due to mucotoxic drugs and is known to deteriorate the general health 
significantly, while negatively affecting the quality of life (QOL). Studies have reported that 
low-level laser therapy (LLLT) promotes the tissue healing. The objective of the present study 
was to explore the efficacy of gallium-arsenide (GaAs) laser in treating COM and its impact on 
inflammatory cytokine levels in patients receiving chemotherapy for various malignancies.
Methods: A total of 80 patients with COM received LLLT 6 days/week. OM was graded according 
to the World Health Organization (WHO) grading scale. The outcome parameters were the serum 
levels of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) measured before, during 
and after administration of LLLT.
Results: After LLLT, a significant decrease was found in the mean values of mucositis grade from 
2.35 ± 0.695 to 1.13 ± 0.333 after (P < 0.001). A significant reduction in the level of TNF-α was 
found after LLLT among breast cancer patients (P = 0.0045), but not in head and neck cancer and 
lymphoma patients. A significant reduction was also found in IL-6 level after treatment among 
head and neck and breast cancer patients (P = 0.0307 and 0.019, respectively).
Conclusion: The use of GaAs LLLT in treating COM in patients with various malignancies is well 
tolerated by patients, it results in improvement of mucositis, however; mechanism of action does 
not seem to be completely linked to the change of pro or anti-inflammatory cytokines.
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Introduction
Cancer patients who are receiving chemotherapy or 
radiotherapy are highly susceptible to have a very common 
complication which is oral mucositis (OM). Severe and 
wide spread ulcerated mucositis that happen in cancer 
patients compromise them both physiologically (by the 
tumor) and literally (by cancer therapy) to be placed at an 
increased risk of systemic infection and bleeding which 
can lead to impaired nutritional status and inadequate 
hydration. Consequently, the quality of life (QOL) of 
these patients will be greatly compromised, and can be 
associated with significant morbidity.1,2 The frequency and 
degree of chemotherapy-induced oral mucositis (COM) 
varies according to the used chemotherapeutic regimen. 
In breast cancer patients receiving taxol-anthracyclin-
cyclophosphamide (TAC) combination chemotherapy, 
the average incidence of COM is high and approaches 
65%.3 On the other hand, the average incidence is lower 
(approximately 15%) in lung cancer patients treated with 
the platinum-gemcitabine combination.3 In addition to 
conventional chemotherapeutic agents, the development 
of newer anti-cancer agents, like epidermal growth factor 
receptor inhibitors and mammalian target of rapamycin 
inhibitors, increases the number of drugs that cause oral 
mucosal toxicities in the cancer care setting.4
The panoply of OM symptoms inevitably impacts a 
patients’ QOL and their willingness to continue treatment 
and has a negative impact on them,5 this is due to 
severe pain and burning sensation which is a significant 
component of OM, dysphagia (difficulty in the feeding 
process) whatever food is liquid or solid, dysarthria 
(speech dysfunction due to impaired coordination of the 
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muscles responsible for word articulation), odynophagia 
(difficulty of swallowing due to pain or burning 
sensation), also as oral lesions provide good environment 
for opportunistic infections that can be life-threatening 
infections (septicemia in neutropenic cases), it can also 
have a negative impact in delaying administration of 
radiation therapy and or chemotherapy, dose reduction of 
the chemotherapeutic drugs.6 
The negative impact of OM on cancer patients is not 
limited to pain and physical consequences and extends to 
other aspects of QOL, like the psychological and social 
aspects.7,8 Furthermore, OM may result in a significant 
economic cost.7
Amelioration of mucositis can greatly affect the feeding 
capacity of patients, through pain relief and improving 
symptoms associated with chewing and swallowing. It also 
allows lowering the frequency and cost of hospitalization 
and palliative care.9 The management of OM is necessary 
to improve the QOL of cancer patients and to optimize 
their treatment outcome by preventing treatment 
interruptions.2 Many approaches to manage OM in cancer 
patients have been evaluated in clinical studies; like oral 
hygiene protocols, cryotherapy, benzydamine mouthwash 
and low-level laser therapy (LLLT).10,11 
LLLT was proved to have positive effects on the 
patient’s QOL in cancer patients suffering from an oral 
complication during oncotherapy treatment,12 and it was 
stated that laser therapy should become part of nutritional 
interventions in oncological patients affected by OM.9
LLLT has several applications in the supportive care of 
patients with cancer. For example, LLLT was found to be 
effective in the management of OM, lymphedema, and 
chemotherapy-induced peripheral neuropathy.13 
A systemic literature review was done14 to assess the 
effectiveness of LLLT as a preventive and therapeutic 
modality of OM in cancer patients 27 articles were assessed, 
3 of them were animal studies and 24 were human studies. 
The results showed that LLLT is a noninvasive modality 
for prevention and management of OM with some 
advantages like analgesic effect, inflammation reduction 
and atraumatic repeated use. 
Another systemic review and meta-analysis were 
conducted in which 12 studies were included, 7 studies 
showed that application LLLT in patients put on 
oncotherapy is nearly nine times more effective to prevent 
OM grade >3 than in patients who did not received laser 
therapy. These data dedicate that LLLT is considered a 
prophylactic treatment for patients with OM (grade > 3).15
The evidence that LLLT has a role in treating OM in 
cancer patients justified its inclusion in international 
mucositis management guidelines. The updated 
Multinational Association of Supportive Care in Cancer 
and International Society of Oral Oncology (MASCC/
ISOO) Clinical Practice Guidelines for OM included 
LLLT.10 The MASCC/ISOO guidelines included one 
recommendation and one suggestion for using LLLT. The 
recommendation is to use LLLT to prevent OM in patients 
put on chemotherapy of high doses and being prepared 
for hematopoietic stem cell transplantation. In addition, 
the suggestion is to use it to avoid the development of OM 
in head and neck cancer patients receiving radiotherapy 
without concomitant chemotherapy.10 The available 
evidence as of 2014 was not strong enough to recommend/
suggest the use of LLLT for OM in cancer patients in other 
clinical settings.
Although there is good evidence supporting the 
application of LLLT in patients put on high-dose 
chemotherapy, there is still a need to investigate the 
optimal LLLT characteristics and its feasibility in COM.16
The current study was planned to explore the 
effectiveness of gallium-arsenide (GaAs) laser therapy 
in the healing of COM and its relation to the level of 
inflammatory cytokines; tumor necrosis factor-alpha 
(TNF-α) as well as interleukin-6 (IL-6) in cancer patients.
Methods
Trial Design and Participants
This study is one group pretest-posttest design (quasi-
experimental design). It was conducted at Kasr ElAini 
Center of Clinical Oncology and Nuclear Medicine, 
Cairo, Egypt in the period from January to September 
2017. Eighty patients with COM were selected from the 
out and inpatient clinic.
The study included 80 patients with the following 
eligibility criteria: adult patients (>18 years old), 
pathological diagnosis of cancer (breast, head and neck or 
non-Hodgkin’s lymphoma), recent exposure to inductive 
chemotherapy phase within 2 weeks and OM. Only those 
head and neck cancer patients were included if they did 
not receive radiotherapy. Chemotherapy administered 
using standard protocols and included at least one of 
these agents: cisplatin, 5-fluorouracil, taxanes, vincristine, 
anthracyclines, gemcitabine or methotrexate; and is 
planned to be administered for 4 to 8 cycles with 2 to 3 
weeks intervals. A consent form was signed by all eligible 
patients.
Patients were excluded under the following conditions: 
double malignancy or metastases of unknown origin, 
chemotherapy phases other than inductive, reduced 
mouth opening (<1 cm2), severe uncontrolled collagen 
vascular disease or pregnancy, current smokers.
Assessment of Oral Mucositis
The severity of OM was rated according to the World 
Health Organization (WHO) grading of mucositis scale17 
as follows:
• Score 0: no signs or symptoms.
• Score 1: Oral soreness and erythema.
• Score 2: Oral erythema and ulcers, both solid and 
liquid diets tolerated.
• Score 3: Oral ulcers, liquid diet only.
• Score 4: Oral alimentation impossible.
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Measurement of Pro-inflammatory Cytokines
Serum TNF-α and IL-6 were estimated using enzyme-
linked immunosorbent assay (ELISA). The serum level 
of both cytokines was measured 4 times during the 
whole treatment period of the patient (one time before 
treatment, at the second and fourth weeks of treatment, 
and at the end of treatment).
Laser Therapy
Laser therapy was performed using laser Phyaction CL-
904 device (Uniphy technology, Belgium) with a small 
hand held probe class 3B. The device produces pulsed 
infrared GaAs laser with wavelength of 904 nm, peak 
power of 25 W, pulse duration of 200 ns, and energy 
density of 1 J/cm2.17 
Calibration of the laser Phyaction CL device was 
performed according to the specifications outlined by the 
manufacturer’s service manual before each session.
Treatment with laser therapy was done 6 days/week 
from the start of OM till the end of chemotherapy. Laser 
therapy was applied on each point for 1 minute with 
energy density of 3 J/cm2.
All patients received routine oral care, local antifungal 
and analgesics (acetaminophen) and nutritional support 
during the laser treatment. They were advised to follow 
a daily mouth hygienic care. Photographic picture to the 
oral cavity was taken before and after laser therapy.
Statistical Methods
Data were represented as mean ± standard deviation or 
as percentages when appropriate. Paired sample t test was 
used to test the significant difference in the mucositis 
grade and the level of TNF-α and IL-6 before and after 
LLLT therapy.
Results
The study included 80 cancer patients with COM. Their 
characteristics are shown in Table 1. Almost half of the 
patients had grade 3 OM before starting laser therapy. 
Chi-square test was used to test the significance of the 
difference in mucositis grades before and after treatment. 
The level of significance was set at a P value <0.05.
The average grade of mucositis decreased significantly 
from 2.35 ± 0.695 before LLLT therapy to 1.13 ± 0.333 
after (P < 0.001) as shown in Figure 1. The percentage of 
improvement was 87.5%.
The distribution of mucositis grades before and after 
laser therapy is shown in Table 2. A significant decrease 
in the severity of mucositis was found after therapy. For 
the whole group of patients, the change in TNF-α level 
after treatment was not significant (Table 3). However, a 
significant decrease was found in TNF-α after treatment 
in breast cancer patients but not head and neck and 
lymphoma patients.
For the whole group of patients, the change in IL-6 level 
after LLLT was not significant (Table 4). A significant 
decrease in IL-6 level was found after LLLT among 
head & neck and breast cancer patients. On the other 
hand, a significant increase in its level was found among 
lymphoma patients after laser therapy.
There was no significant correlation between the post-
treatment levels of TNF-α and IL-6 in patients with 
head and neck cancer (r = -0.9159, P = 0.263), lymphoma 
patients (r = 0.6835, P = 0.5209), nor breast cancer patients 
(r = 0.8431, P = 0.1569).
Table 1. Patients’ Characteristics
Character Value Percent
Age (y)










Head and neck cancer 33 41.3%
Non-Hodgkin’s lymphoma 28 35%





Mean of WHO assessment scale pre-treatment ± SD 2.35 ± 0.695
Figure 1. Grade of OM Before and After GaAs LLLT.





No. % No. %
1 10 12.5 70 87.5 0.001
2 32 40 10 12.5
3 38 47.5 0 0
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Discussion
This work was conducted to explore the effectiveness 
of GaAs LLLT in treating COM in patients with three 
types of cancer, breast, head and neck cancers and non-
Hodgkin’s lymphoma. Overall, the results of the current 
study showed that GaAs LLLT is effective in treating 
COM. Our results confirm the accumulating evidence 
that LLLT is a therapeutic modality that is effective in 
treating OM in cancer patients.2,10
The strong evidence that LLLT has a role in the 
management of OM resulting from anti-cancer therapy 
has led to its inclusion in international mucositis 
management guidelines. The MASCC/ISOO guidelines 
recommended LLLT to prevent OM in patients put on 
high-dose chemotherapy and are being prepared for 
hematopoietic stem cell transplantation and suggested 
to use it to prevent OM in head and neck cancer 
patients receiving radiotherapy without concomitant 
chemotherapy.10 Because there is no sufficient evidence, 
the MASCC/ISOO guidelines did not recommend 
LLLT for the management of COM in patients receiving 
conventional chemotherapy protocols. The current 
study investigated LLLT for COM in cancer patients 
receiving conventional chemotherapy protocols and 
the results concur with those of some other studies,19-21 
we found a significant decrease in the mean scores of 




Mean (±SD) Mean (±SD)
All patients 92.31 ± 17.06 104.9 ± 26.91 0.3964 0.6965
Primary cancer
Head & neck cancer 92.87 ± 41.06 153.2 ± 40.47 1.046 0.354
Lymphoma 105.3 ± 45.87 173.9 ± 22.83 1.338 0.2518
Breast cancer 82.13 ± 14.54 17.05 ± 2.267 4.424 0.0045




Mean (±SD) Mean (±SD)
All patients 99.23 ± 11.19 59.93 ± 18.50 1.818 0.0827
Primary cancer
Head & neck cancer 94.10 ± 27.17 17.30 ± 2.676 2.813 0.0307
Lymphoma 104.1 ± 12.23 145.4 ± 9.817 2.634 0.0389
Breast cancer 99.48 ± 21.74 26.93 ± 6.813 3.185 0.0190
Figure 2. Male Patient With Oral Mucositis (A) before and (B) 
GaAs LLLT.
A B
mucositis after LLLT. Grade 3 mucositis decrease from 
48% before treatment with LLLT to 0% after treatment. 
In their randomized controlled trial, they found that 
prophylactic LLLT reduced significantly the grade of 
COM, xerostomia, and pain in a group of adult cancer 
patients receiving chemotherapy.19
However, the ability of LLLT to reduce the grade of 
COM is inconsistent among studies. In a randomized 
controlled trial conducted,20 the time to healing of 
mucositis and pain were significantly less in patients 
treated with laser. However, there was no significant 
difference in the grade of COM. Similarly, in another 
randomized controlled trial conducted,21 LLLT reduced 
pain significantly, but not the grade of COM in young 
cancer patients.
The results of the current study and those of other 
studies highlight the need for further clinical trials 
to evaluate the role of LLLT in COM among patients 
receiving conventional chemotherapeutic protocols.
Cytokines play a major role in the pathogenesis of 
anti-cancer therapy induced OM and understanding 
their role may be helpful in developing management 
strategies.10,22,23 Among these, are the pro-inflammatory 
cytokines IL-6 and TNF-α which were studied and 
conducted in more than one study,22-24 in which they 
examined the impact of LLLT on inflammatory cytokines 
during COM among patients undergoing hematopoietic 
stem cell transplantation. They found a significant 
difference in plasma level of IL-10 only. No significant 
difference was found in other mediators, TNF-α, IL-6, 
IL-1β, TGF-β. They concluded that the mechanism by 
which LLLT reduces COM may not be completely linked 
to the modulation of inflammatory cytokines levels.24 
Similar to their study,24 in our study, TNF-α did not differ 
significantly after treating COM in head and neck cancer 
and lymphoma patients. However, there was significant 
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decrease in TNF-α in breast cancer patients. Unlike their 
study,25 a significant change was found in IL-6 level. 
However, the change was differential according to the 
tumor type. Serum level of IL-6 decreased in patients 
with head and neck and breast cancer, and increased in 
patients with lymphoma after laser therapy, this may be 
due to the role of IL‐6 expression in cellular sensitivity 
to LLLT.26
The findings of the current study and those of other 
studies show that the relation between the healing effect 
of LLLT and modulation of inflammatory cytokines in 
COM is not completely understood and needs further 
investigation. Since one of the major limitations of 
present study is the lack of a control group; a randomized 
controlled trial would yield better evidence for clinical 
application.
There are other areas that need exploration, like the 
combination of LLLT with other mucositis treatment 
modalities. The addition of cryotherapy to laser therapy 
resulted in significantly more reduction in the severity 
and duration of melphalan-induced OM when compared 
to laser therapy alone.27 In a recent RCT, the combination 
of LLLT and photochemotherapy resulted in significantly 
more reduction in the severity of COM when compared 
to LLLT alone in young cancer patients.28
Conclusion
Regarding the findings of the current study, the use 
of GaAs LLLT in the management of COM in cancer 
patients receiving conventional chemotherapy is well 
tolerated and results in the improvement of OM. It is able 
to reduce the proinflammatory cytokines; IL6 and TNF-α 
in head and neck cancer and breast cancer patients. 
Therefore it may be useful to improve the symptoms of 
chemotherapy- induced OM.
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